Members of the MyoD family of musclespecific basic helix-loop-helix (bHLH) However, a number of skeletal muscle genes that can be activated by the myogenic bHLH factors lack E-boxes in their control regions, suggesting that these factors can also act through indirect mechanisms to activate muscle-specific gene expression (21-24). Mutational analysis of the myogenic bHLH factors has revealed several structural domains that cooperate to initiate muscle gene expression (Fig. 1) . The bHLH region is required for DNA binding and dimerization of myogenic bHLH factors with E proteins, but this region alone does not efficiently activate myogenesis. Transcription activation domains are located in the N and C termini of the myogenic factors and are important for muscle gene activation (reviewed in ref.
within a genetic pathway to control skeletal muscle development. Mutational analyses ofthese factors suggested that their DNA binding domains mediated interaction with a coregulator required for activation of muscle-specific transcription. Members of the myocyte enhancer binding factor 2 (MEF2) family of MADS-box proteins are expressed at high levels in muscle and neural cells and at lower levels in several other cell types. MEF2 factors are unable to activate muscle gene expression alone, but they potentiate the transcriptional activity of myogenic bHLH proteins. This potentiation appears to be mediated by direct interactions between the DNA binding domains of these different types of transcription factors. Biochemical and genetic evidence suggests that MEF2 factors are the coregulators for myogenic bHLH proteins. The presence of MEF2 and cell-specific bHLH proteins in other cell types raises the possibility that these proteins may also cooperate to regulate other programs of cell-specific gene expression. We present a model to account for such cooperative interactions.
Cell lineage determination and differentiation during embryonic development involves the establishment of unique regulatory programs that direct cell type-restricted patterns of gene expression. Members of the basic helix-loop-helix (bHLH) family of transcription factors have been shown to control determination and differentiation of a variety of cell types, including skeletal muscle, neurons, and hematopoietic cells. In the skeletal muscle lineage, the four myogenic bHLH factors, MyoD, myogenin, Myf5, and MRF4, compose a regulatory pathway that establishes myoblast identity and controls terminal differentiation (reviewed in refs. [1] [2] [3] [4] . When introduced into nonmuscle cell types, each of these factors can activate the entire program for skeletal myogenesis. Biochemical and genetic experiments have suggested that the myogenic bHLH factors rely on a coregulator to activate muscle gene transcription. Here we review evidence indicating that members of the myocyte enhancer binding factor 2 (MEF2) family of MADSbox transcription factors act as coregulators for myogenic bHLH factors, and we consider the possibility that this type of combinatorial control may represent a more general mechanism for the regulation of cell type-specific transcription.
Regulation of Muscle Transcription by Myogenic bHLH Proteins
Members of the bHLH family of transcription factors share homology within a basic domain and an adjacent helix-loophelix motif. Cell-specific bHLH factors like the myogenic regulators dimerize preferentially with a ubiquitous class of bHLH proteins known as E proteins, which includes E12, E47, and HEB (5, 106) . The resulting heterodimers bind the consensus E-box DNA sequence CANNTG (reviewed in refs. [6] [7] [8] . E-boxes have been identified in the control regions of many skeletal muscle-specific structural genes where they are required for activation by myogenic bHLH factors (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . However, a number of skeletal muscle genes that can be activated by the myogenic bHLH factors lack E-boxes in their control regions, suggesting that these factors can also act through indirect mechanisms to activate muscle-specific gene expression (21) (22) (23) (24) .
Mutational analysis of the myogenic bHLH factors has revealed several structural domains that cooperate to initiate muscle gene expression (Fig. 1) . The bHLH region is required for DNA binding and dimerization of myogenic bHLH factors with E proteins, but this region alone does not efficiently activate myogenesis. Transcription activation domains are located in the N and C termini of the myogenic factors and are important for muscle gene activation (reviewed in ref. 3 ). These activation domains do not confer muscle specificity to transcription and can be replaced with the activation domain of the viral coactivator VP16 (25) (26) (27) .
Evidence for a Coregulator that Recognizes the Basic Regions of Myogenic bHLH Factors
The basic regions of the myogenic factors have been the focus of intense interest. There is a 12-amino acid segment of the basic regions of these factors that is necessary and sufficient for DNA binding with the HLH region (Fig. 1) . Eight of these 12 residues are conserved in E proteins. Among the nonconserved residues, an alanine and a threonine in the center of the DNA binding domain are required for muscle gene activation, but these residues are not required for DNA binding (28, 29) . Mutants of the myogenic factors in which these residues are replaced with asparagines, which are found at the corresponding positions in the DNA binding domains of E proteins, retain the ability to bind DNA, but they cannot activate muscle transcription. Conversely, if the asparagines in the basic region of E12 are -eplaced with alanine-threonine and an aspartic acid at the junction of the basic region and of helix-1 of E12 is replaced with a lysine, which is found at that position in the myogenic factors, these residues confer upon E12 the ability to activate myogenesis (30) . The fact that DNA binding activity is not affected by these substitutions suggests that these amino acids mediate an event subsequent to DNA binding that is essential for activation of muscle gene expression; it has been Proc. Natl. Acad. Sci. USA 93 (1996) (29) .
proposed that theses amino acids are necessary for interaction with a coregulator required for muscle gene activation.
The crystal structure of MyoD bound to DNA predicts that the alanine and threonine residues in the basic region are buried in the major groove of the DNA binding site and are inaccessible for interaction with a putative coregulator (31 (39) , and it has also been detected at lower levels in a variety of other cell types (40, 41) .
In vertebrates, MEF2 DNA binding activity is encoded by four genes, referred to as mef2a-d (39, 40, [42] [43] [44] [45] [46] [47] [48] . There is also a single MEF2 gene in Drosophila (32) (33) (34) (62) (63) (64) . These conclusions are supported by the crystal structure of the DNA binding region of SRF with its DNA binding site (65) . The DNA binding domain of SRF is composed of three distinct subdomains. The MADS-box contains an extended a-helical region at the N-terminal end that mediates DNA binding, whereas the C-terminal region adopts a ,B-strand conformation that is oriented away from the DNA and is involved in subunit dimerization (65) . Immediately C-terminal to the MADS-box of SRF is a region of (3- During brain development, MEF2 factors show highly localized patterns of expression that correlate with differentiation of multiple neuronal cell types (69) . Late in embryogenesis, MEF2A, MEF2B, and MEF2D transcripts become expressed in a wide range of cell types, whereas MEF2C expression remains restricted primarily to skeletal muscle, brain, and spleen (43, 44) .
MEF2 and Myogenic bHLH Factors Regulate the Expression of Each Other
Forced expression of the myogenic bHLH factors can induce MEF2 DNA binding activity in cells that undergo myogenic conversion, such as 10TI/2 cells, as well as in cells that are refractory to myogenic conversion, such as CV-1 kidney cells (70, 71) . These results suggest that MEF2 factors lie in a regulatory pathway downstream of the myogenic bHLH factors (Fig. 4) . However, MEF2 sites in the promoters of the mouse myogenin (14, (72) (73) (74) and MRF4 genes (19, 20) and the Xenopus MyoDa gene (75) are required for expression in muscle cells, indicating that MEF2 also plays a role in the regulation of the myogenic bHLH genes. The region of the Quail MyoD promoter that is required for tissue-specific expression also contains MEF2 binding sites (76) , but their role in MyoD regulation has not yet been determined. Since MEF2 factors are expressed in the skeletal muscle lineage after the myogenic bHLH factors, it is most likely that they are involved in amplification or maintenance of myogenic bHLH gene expression rather than in the initial activation of these genes. letal muscle lineage, but in contrast to the myogenic site and two E-boxes (17). Li and Capetanaki (17) showed that ctors, they are also expressed in other lineages.
MEF2 and the Myogenic bHLH Proteins Act
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g heart, as well as in smooth muscle cells (61, 67, 68 (1996) Proc. Natl. Acad. Sci. USA 93 (1996) (79) . These results differ from another study which reported that MEF2 acted as a myogenic determination factor that could induce conversion of fibroblasts to skeletal muscle with an efficiency comparable to that of MyoD and myogenin (77) . The basis for these differences has not been resolved.
Although MEF2 factors, in our hands, are unable to induce myogenesis alone, they enhanced the ability of the myogenic bHLH factors to induce muscle gene expression, suggesting that they might function as cofactors for myogenic bHLH proteins. Based on these results, we initially reasoned that mutants of MEF2 that were able to dimerize but not bind DNA would act in a dominant negative manner to block the ability of myogenic bHLH factors to activate myogenesis. However, these mutants also potentiated the myogenic activity of myogenin and MyoD to the same extent as wild-type MEF2 (79) . This suggested that this potentiation between myogenic bHLH factors and MEF2 did not require binding of MEF2 to DNA and raised the possibility that these two types of factors might interact. Indeed, subsequent immunoprecipitation experiments showed that MEF2 can interact with heterodimers formed between myogenic bHLH factors and E12, but it cannot recognize either of these types of bHLH proteins alone. The interaction between myogenic bHLH factors, E12, and MEF2 can also be demonstrated in vivo using a GAL4-based tri-hybrid assay. The inability of MEF2 to recognize myogenic bHLH factors or E proteins alone suggests that heterodimerization of these bHLH factors creates a specific determinant for MEF2 recognition.
To determine whether cooperativity between myogenic bHLH and MEF2 factors requires direct protein-protein interactions, we have examined an extensive series of MEF2 mutants. Point mutations in the MADS-box that eliminate DNA binding activity of MEF2 do not significantly affect the ability to interact with the myogenin/E12 heterodimer or the ability to synergize with myogenin in myogenic conversion. Both the MADS and the MEF2 domains are required for interaction with the myogenic bHLH/E12 heterodimer. However, we have identified no single point mutation that significantly diminishes this interaction, suggesting that the binding surface is widely distributed over an extended region of the MADS and MEF2 domains. In every case examined thus far, the ability to interact with the myogenic bHLH/E12 heterodimer correlates with the ability of an MEF2 mutant to synergize with myogenin or MyoD in myogenic conversion.
We have also examined the potential of several myogenin and MyoD mutants to cooperate with MEF2 factors in myogenic conversion. Whereas the bHLH region of myogenin is unable to initiate myogenesis in transfected 1OT1/2 cells (26), when expressed with MEF2, it acquires full myogenic potential (79) (Fig. 5) . The finding that MEF2 can confer myogenic potential to the bHLH region of myogenin suggests that the bHLH domain of the myogenic factor bound to DNA in vivo recruits MEF2, resulting in synergistic activation of myogenesis because of the presence of the transactivation domain provided by MEF2. That a transcription activation domain is required in one of the two factors is demonstrated by the failure of an MEF2C mutant lacking the C-terminal transactivation domain to confer myogenic potential to the bHLH region of myogenin. We believe that the cooperativity between myogenic bHLH and MEF2 factors in muscle gene activation reflects a specific recognition event and not simply a greater degree of transcriptional activity in the presence of the two factors because the MADS and MEF2 domains of MEF2C lack transcriptional activity on their own, but they are able to augment the myogenic potential of full-length myogenin or MyoD.
The synergy between myogenic bHLH and MEF2 factors in activation of the endogenous myogenic program or artificial reporters (see below) depends on the myogenic residues (alanine and threonine) in the DNA binding domains of myogenic bHLH proteins and is not observed with a MyoD mutant containing the E12 basic region (79) . Thus, the same residues in the myogenic bHLH factors that were originally predicted from mutational analyses to mediate interaction with a myogenic coregulator are required for synergy between the DNA binding domains of myogenic bHLH factors and MEF2. Whether the myogenic residues in the basic region of MyoD are required for interaction with MEF2 or whether interaction and synergy are separable events remains to be determined. It is conceivable, for example, that MyoD mutants lacking the alanine and threonine residues in the basic region can form a complex with MEF2 but that they cannot adopt a transcriptionally active conformation.
To further define the potential interactions between myogenic bHLH and MEF2 factors, we have examined the ability of these factors to activate a series of artificial reporter genes containing binding sites for one factor or the other. Deletion mutants of myogenin and E12 containing only the bHLH regions are unable to activate an artificial E-box-dependent reporter gene when cotransfected in fibroblasts because they lack functional transactivation domains. However, if these mutants are expressed with a full-length MEF2 protein, strong transactivation is seen, presumably because the myogenin/E12
heterodimer acts as a platform to recruit MEF2 and its Colloquium Paper: Molkentin transactivation domain to the promoter. This type of recruitment can also occur when MEF2 is bound to DNA. A mutant MEF2 protein consisting of just the MADS and MEF2 domains is unable to transactivate an MEF2-dependent reporter. However, if full-length myogenin and E12 are also coexpressed with this type of mutant, a high level of transactivation is observed. These data demonstrate that either factor can interact with the other when one is bound to DNA.
In these types of indirect transactivation assays, it is formally possible that the factor providing the transcriptional activation domain may be interacting with the target plasmid through a cryptic binding site or that its binding specificity is altered by interaction with the factor bound to its DNA site. However, we believe this is unlikely because this transactivation occurs on several different types of basal promoters linked to multimerized E-boxes or MEF2 sites, and these different promoters do not share obvious sequence homology. Moreover, if the site for the binding factor that serves as the platform is mutated, all synergy is lost. Also, point mutants in MEF2 that eliminate its DNA binding potential do not affect its ability to interact and potentiate transactivation in these assays, providing further evidence that MEF2 does not need to bind DNA to activate transcription through an E-box when the bHLH factors are bound there.
It should be pointed out that these types of assays in which MEF2 and myogenic bHLH factors are overexpressed with reporter genes linked to multimerized E-boxes or MEF2 sites represent a highly simplified system for analyzing potential interactions between these factors and that the control of native promoters and enhancers is likely to be much more complex. The muscle creatine kinase enhancer, for example, contains two E-boxes and two MEF2 sites, and mutations in the right E-box eliminate almost all enhancer activity in muscle cells (16) , which indicates that the types of protein-protein interactions we have documented with artificial promoters cannot explain the control of all muscle genes. It seems likely that the ability of native muscle genes to respond to myogenic bHLH and MEF2 factors will depend on a variety of variables, including the distance of E-boxes or MEF2 sites from the basal promoter, the presence of other positive and negative factors Proc. Natl. Acad. Sci. USA 93 (1996) Proc. Natl. Acad. Sci. USA 93 (1996) Fig. 6 . Some muscle-specific genes contain only E-box sequences in their control regions, yet MEF2 may still contribute to their activation by interaction with myogenic bHLH proteins bound to these sites, as depicted in model 1 (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Some muscle-specific genes lack E-boxes in their control regions, but they contain MEF2 sites that may allow for indirect activation by myogenic bHLH proteins via interaction with MEF2 bound to these sites, as depicted in model 2 (22) (23) (24) (19, 20) and Xenopus MyoDa promoters (75) . The TATA box of the myoglobin promoter also binds MEF2 (81) and is required for muscle-specific expression; this TATA box cannot be substituted with that of the SV40 promoter (82 Protein kinase C is also a potent inhibitor of muscle gene activation. One mechanism by which protein kinase C inhibits myogenesis is through phosphorylation of the threonine in the basic region of myogenin, which prevents DNA binding (92) . If this threonine is replaced with aspartic acid to mimic phosphorylation, the ability of myogenin to synergize with MEF2 in transcriptional activation of MEF2-dependent reporter genes is lost (79) . This suggests that in addition to blocking DNA binding, phosphorylation of myogenin by protein kinase C may interfere with the ability of myogenin to interact with MEF2.
Possible Mechanisms for Synergy
The transfection assays and coimmunoprecipitation experiments demonstrate that the DNA binding domains of myogenic bHLH and MEF2 factors play a dual role in DNAprotein and protein-protein interactions; but how do the interactions between these factors actually result in cooperative activation of muscl-e transcription? Because both types of factors can bind DNA independently and contain transcription activation domains, it is perhaps surprising that they rely on each other to coregulate the myogenic program. One possible explanation for this interdependence is that the ternary complex formed between the myogenic bHLH factor, E12, and MEF2 creates a unique surface that interacts with the transcriptional machinery more efficiently than any of the individual factors alone. Alternatively, MEF2 might induce a conformational change in the myogenic bHLH factor, enabling it to activate transcription. In this regard, it has been reported that the activation domain of MyoD is normally cryptic and that the alanine and threonine residues in the basic region are required for this domain to be unmasked upon DNA binding (30) . It is also conceivable that the three proteins, MyoD, E12, and MEF2, act through a concerted mechanism to activate transcription more efficiently together than alone. Resolution of these questions will require identification of the targets for the ternary complex in the transcriptional machinery.
MEF2 as a Potential Cofactor for Other Tissue-Restricted bHLH Proteins
The D-mef2 loss-of-function phenotype suggests that in addition to its role in skeletal muscle, MEF2 is required for differentiation of cardiac and visceral muscle. The notion that MEF2 acts as a cofactor for myogenic bHLH proteins, but does not itself activate skeletal muscle transcription, is consistent with the fact that MEF2 factors are expressed at high levels in cardiac and smooth muscle and in neurons. Based on the inability of cardiac and visceral muscle cells to differentiate in Drosophila embryos lacking MEF2, we propose that MEF2 may serve as a cofactor for other cell-specific transcription factors, bHLH or otherwise. Although our studies indicate that the myogenic amino acids in the basic regions of myogenic bHLH factors are required for synergy with MEF2, the possibility that MEF2 might also recognize the basic regions of other bHLH factors cannot be ruled out.
MEF2 DNA binding sites are present in the control regions of numerous cardiac-specific promoters and enhancers, such as the a-MHC, MLC-2v, and the ANF genes. Detailed studies on the MLC-2v (23, (93) (94) (95) (96) ) and a-MHC promoters (97) The finding that MEF2 acts as an accessory factor for myogenic bHLH factors is consistent with the functions of MADS-box proteins in other systems. SRF, for example, interacts with the homeodomain protein Phox, resulting in an increase in SRF's DNA binding activity (103) . SRF also interacts with a number of ETS-domain proteins that form ternary complexes with adjacent binding sites (reviewed in ref. 66) . In Saccharomyces cerevisiae, the MADS-box factor MCM1 interacts with the accessory factors al and a2 (104) to control cell type-specific genes and with the factor STE12 to control pheromone responsiveness (105) . Given that other MADS-box proteins cooperate with regulatory factors that bind DNA sequences adjacent to the MADS-box binding site, it will also be of interest to analyze the sequences that flank MEF2 sites to determine if they play a role in determining MEF2 specificity in cell lineages other than skeletal muscle.
